ZA200805285B - Indolone compounds useful to treat cognitive impairment - Google Patents

Indolone compounds useful to treat cognitive impairment

Info

Publication number
ZA200805285B
ZA200805285B ZA200805285A ZA200805285A ZA200805285B ZA 200805285 B ZA200805285 B ZA 200805285B ZA 200805285 A ZA200805285 A ZA 200805285A ZA 200805285 A ZA200805285 A ZA 200805285A ZA 200805285 B ZA200805285 B ZA 200805285B
Authority
ZA
South Africa
Prior art keywords
cognitive impairment
compounds useful
treat cognitive
indolone compounds
indolone
Prior art date
Application number
ZA200805285A
Other languages
English (en)
Inventor
Thomas P Blackburn
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of ZA200805285B publication Critical patent/ZA200805285B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200805285A 2005-12-09 2006-12-08 Indolone compounds useful to treat cognitive impairment ZA200805285B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74885105P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
ZA200805285B true ZA200805285B (en) 2009-12-30

Family

ID=37903540

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805285A ZA200805285B (en) 2005-12-09 2006-12-08 Indolone compounds useful to treat cognitive impairment

Country Status (23)

Country Link
EP (2) EP2241316A1 (fr)
JP (1) JP5336194B2 (fr)
KR (1) KR20080077646A (fr)
CN (1) CN101378750B (fr)
AT (1) ATE480234T1 (fr)
AU (1) AU2006326665B2 (fr)
BG (1) BG110157A (fr)
BR (1) BRPI0620034A2 (fr)
CA (1) CA2633829A1 (fr)
CZ (1) CZ2008423A3 (fr)
DE (1) DE602006016849D1 (fr)
EA (1) EA200870027A1 (fr)
ES (1) ES2349675T3 (fr)
HR (1) HRP20080254A2 (fr)
IL (1) IL192022A0 (fr)
IS (1) IS8733A (fr)
MX (1) MX2008007377A (fr)
NO (1) NO20083042L (fr)
PL (1) PL386471A1 (fr)
RS (1) RS20080257A (fr)
SK (1) SK500262008A3 (fr)
WO (1) WO2007070362A1 (fr)
ZA (1) ZA200805285B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527324A4 (fr) 2010-01-20 2013-08-07 Mitsubishi Gas Chemical Co Composé ester de cyanate et produit durci obtenu à partir de celui-ci

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK69693D0 (da) * 1993-06-14 1993-06-14 Neurosearch As Farven lilla
US20030078271A1 (en) 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
TW200410937A (en) * 2002-08-07 2004-07-01 Synaptic Pharma Corp 3-imino-2-indolones for the treatment of depression and/or anxiety
WO2004014307A2 (fr) * 2002-08-07 2004-02-19 Synaptic Pharmaceutical Corporation Antagonistes de gal3 destines au traitement de douleurs neuropathiques
WO2004014376A1 (fr) * 2002-08-07 2004-02-19 Synaptic Pharmaceutical Corporation Antagonistes du recepteur gal3 pour le traitement des troubles affectifs

Also Published As

Publication number Publication date
IL192022A0 (en) 2009-08-03
NO20083042L (no) 2008-09-08
WO2007070362A1 (fr) 2007-06-21
PL386471A1 (pl) 2009-04-14
EA200870027A1 (ru) 2009-12-30
HK1127736A1 (en) 2009-10-02
BRPI0620034A2 (pt) 2011-10-25
ATE480234T1 (de) 2010-09-15
EP1957067A1 (fr) 2008-08-20
HRP20080254A2 (hr) 2008-09-30
IS8733A (is) 2008-06-20
EP2241316A1 (fr) 2010-10-20
AU2006326665B2 (en) 2012-11-15
AU2006326665A1 (en) 2007-06-21
RS20080257A (sr) 2009-05-06
BG110157A (en) 2008-12-30
CN101378750A (zh) 2009-03-04
DE602006016849D1 (de) 2010-10-21
EP1957067B1 (fr) 2010-09-08
CN101378750B (zh) 2012-07-18
JP5336194B2 (ja) 2013-11-06
SK500262008A3 (sk) 2009-03-05
KR20080077646A (ko) 2008-08-25
CA2633829A1 (fr) 2007-06-21
CZ2008423A3 (cs) 2009-08-05
JP2009518431A (ja) 2009-05-07
MX2008007377A (es) 2008-10-29
ES2349675T3 (es) 2011-01-10

Similar Documents

Publication Publication Date Title
LUC00217I2 (fr)
TW200730523A (en) Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
PT2368550E (pt) Modulador do receptor de androgénios para o tratamento de cancro da próstata e doenças associadas ao receptor de androgénios
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
WO2007078813A8 (fr) DÉRIVÉS DE 2-AMINO-5-PIPÉRIDINYLIMIDAZOLONE ET APPLICATIONS À LA MODULATION DE LA ß-SECRÉTASE
TW200510303A (en) Novel compounds
WO2005039504A3 (fr) Composes et methodes permettant de traiter les maladies et etats pathologiques lies au recepteur 2 de type toll
WO2008155533A3 (fr) Composés de traitement
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
TN2010000155A1 (en) Organic compounds
WO2007047447A3 (fr) Analogues de compose diuretique ou de type diuretique
TW200605871A (en) Carboxamido opioid compounds
SI1585510T1 (sl) Alfa-aminoamidni derivati, koristni kot sredstva proti migreni
IL192022A0 (en) Indolone compounds useful to treat cognitive impairment
TW200642690A (en) Composition for treating central nervous system disorders
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
TW200742580A (en) Methods for treating nephrolithiasis
HU0201394D0 (fr)
TW200744577A (en) Method for treating osteoarthritis
IL170519A0 (en) Use of a fibrate and orlistat for the treatment of obesity
EP1890711A4 (fr) Composés pour le traitement ou la prévention de pathologies ou de troubles liés à l amine oxydase
WO2004065932A3 (fr) Procedes pour identifier les modulateurs de la glycosylation cellulaire au moyen de gtrap3-18
WO2003092478A3 (fr) Methodes permettant de traiter les troubles neuronaux
PL1819354T3 (pl) Sposoby i związki do leczenia cukrzycy